| Form | Liquid |
|---|---|
| Host Species | Chimeric |
| Clonality | Monoclonal |
| Isotype | IgG4-nd |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Concentration | 3.79mg/ml |
| Endotoxin Level | Please contact the lab for this information. |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Species Reactivity | Human |
| Target | CD49 antigen-like family member E, Integrin alpha-F, ITGA5, VLA-5, Fibronectin receptor subunit alpha, CD49e, Integrin alpha-5, FNRA |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Expression System | Mammalian Cells |
| Accession Number | P08648 |
| Background | Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs). • Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer., PMID:35338412 |
| Alternative Names | 558480-40-3 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |